ClinicalTrials.gg
CompletedNCT02799602ARASENSUpdated Dec 4, 2025Results posted

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

A Phase 3 interventional study of BAY1841788 / darolutamide (ODM-201) and Standard ADT (androgen deprivation therapy) in Metastatic Hormone-sensitive Prostate Cancer, sponsored by Bayer. Completed at 322 sites in 23 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,306
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
2nd of 59
1,306 · median 80
Started
2016
the only one that year
Phase 3
12 of 59
5 open now
Registered
6th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2016, is one of 12 in phase 3, and was the 6th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total daily dose of 1200 mg, in addition to standard androgen deprivation therapy (ADT) and docetaxel. Subjects will be stratified at randomization for the extent of disease and for Alkaline Phosphatase levels. All subjects will be treated with ADT as standard therapy. Six cycles of docetaxel will be administered after randomization.

The subjects considered for inclusion in the study will have metastatic prostate cancer and will be candidates for ADT and docetaxel.

Treatment with darolutamide (ODM-201)/placebo will be administered until symptomatic progressive disease, change of antineoplastic therapy, unacceptable toxicity, until subject withdraws consent, withdrawal from the study at the discretion of the investigator or his/her designated associate(s), death, non-compliance, or if sponsor terminates the study.

03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of prostate.
  • disease
  • Candidates for ADT and docetaxel.
  • Started ADT with or without first generation anti androgen, but no longer than 12 weeks before randomization
  • An (ECOG) performance status of 0 or 1
  • Adequate bone marrow, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with: LHRH agonist/antagonists; second generation androgen receptor (AR) inhibitors such as enzalutamide, ARN-509, darolutamide (ODM-201), other AR inhibitors; CYP17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as antineoplastic treatment for prostate cancer; chemotherapy or immunotherapy for prostate cancer prior to randomization.
  • Treatment with radiotherapy/radiopharmaceuticals within 2 weeks before randomization.
  • Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure ( Class III or IV)
  • Had a prior . Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed 5 years before randomization and from which the subject has been disease-free
  • Gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study treatment.
  • Inability to swallow oral medications
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,306 participants (actual)

Study arms

  • Experimental
    BAY1841788 /darolutamide (ODM-201)+standard ADT+Docetaxel

    Co-administration of BAY 1841788 / darolutamide (ODM-201), standard ADT and docetaxel

    Drug: BAY1841788 / darolutamide (ODM-201) · Drug: Standard ADT (androgen deprivation therapy) · Drug: Docetaxel

  • Placebo comparator
    Placebo + standard ADT + Docetaxel

    Co-administration of Placebo matching BAY 1841788 / darolutamide (ODM-201) tablets, standard ADT and docetaxel

    Drug: Standard ADT (androgen deprivation therapy) · Drug: Docetaxel · Drug: Placebo

Interventions

  • DrugBAY1841788 / darolutamide (ODM-201)

    Drug page: Darolutamide

    600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel

  • DrugStandard ADT (androgen deprivation therapy)

    As prescribed by the treating physician.

  • As prescribed by the treating physician.

  • DrugPlacebo

    Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.

06

What researchers measure

Primary outcomes

  1. OS From Date of Randomization Until Death From Any Cause - Number of Events

    Overall survival (OS) was defined as the time from the date of randomization until death from any cause. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. Long-term (Survival) follow-up period: After Active follow-up, patients continued to be contacted approximately every 12 weeks by phone. The end of the Survival follow-up period was defined as when the patient died, was lost to follow-up, withdrew consent, or at the end-of-study.

    Time frame: From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)

  2. OS From Date of Randomization Until Death From Any Cause - Month

    Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. Long-term (Survival) follow-up period: After Active follow-up, patients continued to be contacted approximately every 12 weeks by phone. The end of the Survival follow-up period was defined as when the patient died, was lost to follow-up, withdrew consent, or at the end-of-study. Median, percentile and other 95% CIs were computed using Kaplan-Meier estimates. NA = Value cannot be estimated due to censored data

    Time frame: From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)

Secondary outcomes

  1. Number of Participants With TEAEs

    TEAEs = Treatment-emergent adverse events, were defined as any event(s) arising or worsening after the first dose of darolutamide or placebo, until 30 days after the last dose of darolutamide or placebo administration.

    Time frame: From the first dose of darolutamide or placebo until 30 days after the last dose of darolutamide or placebo administration up to cut-off date for the final completion analysis 11 APR 2023 (approximately 77 months)

  2. Time to Castration-Resistant Prostate Cancer (CRPC) - Number of Events

    Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of one of the following events: PSA progression, Radiological progression by bone lesions, or Radiological progression by soft tissue and visceral lesions. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the first occurrence of an CRPC event up to 25 OCT 2021 cut-off date approximately 59 months

  3. Time to Castration-Resistant Prostate Cancer (CRPC) - Month

    Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of one of the following events: PSA progression, Radiological progression by bone lesions, or Radiological progression by soft tissue and visceral lesions. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

    Time frame: From randomization of the first participant to the first occurrence of an CRPC event up to 25 OCT 2021 cut-off date approximately 59 months

  4. Time to Pain Progression - Number of Events

    Time to pain progression was defined as the time from randomization to the first date a patient experienced pain progression. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the first occurrence of a pain progression event up to 25 OCT 2021 cut-off date approximately 59 months

  5. Time to Pain Progression - Month

    Time to pain progression was defined as the time from randomization to the first date a patient experienced pain progression. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

    Time frame: From randomization of the first participant to the first occurrence of a pain progression event up to 25 OCT 2021 cut-off date approximately 59 months

  6. Symptomatic Skeletal Event Free Survival (SSE-FS) - Number of Events

    Symptomatic skeletal event-free survival (SSE-FS) was defined as the time from randomization to the first occurrence of an SSE or death from any cause, whichever occurred first. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the first occurrence of an SSE event or death from any cause, whichever occurred first up to 25 OCT 2021 cut-off date approximately 59 months

  7. Symptomatic Skeletal Event Free Survival (SSE-FS) - Month

    Symptomatic skeletal event-free survival (SSE-FS) was defined as the time from randomization to the first occurrence of an SSE or death from any cause, whichever occurred first. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

    Time frame: From randomization of the first participant to the first occurrence of an SSE event or death from any cause, whichever occurred first up to 25 OCT 2021 cut-off date approximately 59 months

  8. Time to First Symptomatic Skeletal Event (SSE) - Number of Events

    Time to the first SSE was defined as the time from randomization to the first occurrence of an SSE. Identical to the definition used for SSE-FS. Death was not considered as an event in this endpoint. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the first occurrence of an SSE event up to 25 OCT 2021 cut-off date approximately 59 months

  9. Time to First Symptomatic Skeletal Event (SSE) - Month

    Time to the first SSE was defined as the time from randomization to the first occurrence of an SSE. Identical to the definition used for SSE-FS. Death was not considered as an event in this endpoint. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

    Time frame: From randomization of the first participant to the first occurrence of an SSE event up to 25 OCT 2021 cut-off date approximately 59 months

  10. Time to Initiation of Subsequent Antineoplastic Therapy - Number of Events

    Time to initiation of subsequent systemic antineoplastic therapy was defined as the time from randomization to the initiation of first subsequent systemic antineoplastic therapy. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the initiation of first subsequent systemic antineoplastic therapy up to 25 OCT 2021 cut-off date approximately 59 months

  11. Time to Initiation of Subsequent Antineoplastic Therapy - Month

    Time to initiation of subsequent systemic antineoplastic therapy was defined as the time from randomization to the initiation of first subsequent systemic antineoplastic therapy. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

    Time frame: From randomization of the first participant to the initiation of first subsequent systemic antineoplastic therapy up to 25 OCT 2021 cut-off date approximately 59 months

  12. Time to Worsening of Disease-Related Physical Symptoms - Number of Events

    Time to worsening of disease-related physical symptoms was defined as the time from randomization to the first date a patient experienced an increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the first increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire up to 25 OCT 2021 cut-off date approximately 59 months

  13. Time to Worsening of Disease-Related Physical Symptoms - Month

    Time to worsening of disease-related physical symptoms was defined as the time from randomization to the first date a patient experienced an increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the first increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire up to 25 OCT 2021 cut-off date approximately 59 months

  14. Time to Initiation of Opioid Use for ≥7 Consecutive Days - Number of Events

    Time to the initiation of opioid use for ≥7 consecutive days was defined as the time fromrandomization to the date of the first opioid use for ≥7 consecutive days. Data of opioid use related to cancer pain was included in the analysis, and opioid use for non-malignant causes was excluded. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

    Time frame: From randomization of the first participant to the first opioid use for ≥7 consecutive days up to 25 OCT 2021 cut-off date approximately 59 months

  15. Time to Initiation of Opioid Use for ≥7 Consecutive Days - Month

    Time to the initiation of opioid use for ≥7 consecutive days was defined as the time fromrandomization to the date of the first opioid use for ≥7 consecutive days. Data of opioid use related to cancer pain was included in the analysis, and opioid use for non-malignant causes was excluded. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

    Time frame: From randomization of the first participant to the first opioid use for ≥7 consecutive days up to 25 OCT 2021 cut-off date approximately 59 months

07

Results

Posted Feb 24, 2023

Participant flow

This multinational study was conducted between 30-Nov-2016 First Participant First Visit and 11-Apr-2023 Last Participant Last Visit, in 23 countries/regions: Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Finland, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Russian Federation, South Korea, Spain, Sweden, Taiwan, UK, US

Participant flow — Overall Study
MilestoneDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Started651654
Started treatment651651
Completed00
Not completed651654
Withdrew: Protocol violation10
Withdrew: Physician decision56
Withdrew: Lost to follow-up42
Withdrew: Additional primary malignancy116
Withdrew: Non-compliance with study drug1412
Withdrew: Adverse event associated with clinical disease progression2426
Withdrew: Withdrawal by subject2640
Withdrew: Progressive disease - clinical progression131276
Withdrew: Progressive disease - radiological progression90133
Withdrew: Adverse event not associated with clinical disease progression4927
Withdrew: Death95
Withdrew: Other287118
Withdrew: Study drug never administered03

Outcome measures

PrimaryOS From Date of Randomization Until Death From Any Cause - Number of Events

Overall survival (OS) was defined as the time from the date of randomization until death from any cause. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. Long-term (Survival) follow-up period: After Active follow-up, patients continued to be contacted approximately every 12 weeks by phone. The end of the Survival follow-up period was defined as when the patient died, was lost to follow-up, withdrew consent, or at the end-of-study.

Time frame:
From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)
Reported as:
Count of participants · Participants
OS From Date of Randomization Until Death From Any Cause - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number of patients with event229304
Number of patients censored422350
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = <0.0001 (One-sided p-value.) · Hazard ratio (hr): 0.675 · 95% CI 0.568 to 0.801
SecondaryNumber of Participants With TEAEs

TEAEs = Treatment-emergent adverse events, were defined as any event(s) arising or worsening after the first dose of darolutamide or placebo, until 30 days after the last dose of darolutamide or placebo administration.

Time frame:
From the first dose of darolutamide or placebo until 30 days after the last dose of darolutamide or placebo administration up to cut-off date for the final completion analysis 11 APR 2023 (approximately 77 months)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Any TEAE649643
TESAE306276
TEAE leading to study drug dose modification172112
TEAE leading to permanent discontinuation of study drug9069
TEAE leading to docetaxel dose modification216214
TEAE leading to permanent discontinuation of docetaxel5267
Related to protocol-required procedure6964
Any study drug-related TEAE344309
Study drug-related TESAE3024
Study drug-related TEAE leading to study drug dose modification7541
Study drug-related TEAE leading to permanent discontinuation of study drug2513
SecondaryTime to Castration-Resistant Prostate Cancer (CRPC) - Number of Events

Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of one of the following events: PSA progression, Radiological progression by bone lesions, or Radiological progression by soft tissue and visceral lesions. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the first occurrence of an CRPC event up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Count of participants · Participants
Time to Castration-Resistant Prostate Cancer (CRPC) - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number of patients with event225391
Number of patients censored426263
SecondaryTime to Castration-Resistant Prostate Cancer (CRPC) - Month

Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of one of the following events: PSA progression, Radiological progression by bone lesions, or Radiological progression by soft tissue and visceral lesions. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

Time frame:
From randomization of the first participant to the first occurrence of an CRPC event up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Median · Months
Time to Castration-Resistant Prostate Cancer (CRPC) - Month
MonthsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Time to Castration-Resistant Prostate Cancer (CRPC) - MonthNA (NA to NA)19.1 (16.5 to 21.8)
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = <0.0001 (One-sided p-value.) · Hazard ratio (hr): 0.357 · 95% CI 0.302 to 0.421
SecondaryTime to Pain Progression - Number of Events

Time to pain progression was defined as the time from randomization to the first date a patient experienced pain progression. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the first occurrence of a pain progression event up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Count of participants · Participants
Time to Pain Progression - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number of patients with event222248
Number of patients censored429406
SecondaryTime to Pain Progression - Month

Time to pain progression was defined as the time from randomization to the first date a patient experienced pain progression. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

Time frame:
From randomization of the first participant to the first occurrence of a pain progression event up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Median · Months
Time to Pain Progression - Month
MonthsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Time to Pain Progression - MonthNA (30.5 to NA)27.5 (22.0 to 36.1)
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = 0.0058 (One-sided p-value.) · Hazard ratio (hr): 0.792 · 95% CI 0.660 to 0.950
SecondarySymptomatic Skeletal Event Free Survival (SSE-FS) - Number of Events

Symptomatic skeletal event-free survival (SSE-FS) was defined as the time from randomization to the first occurrence of an SSE or death from any cause, whichever occurred first. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the first occurrence of an SSE event or death from any cause, whichever occurred first up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Count of participants · Participants
Symptomatic Skeletal Event Free Survival (SSE-FS) - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number of patients with event257329
Number of patients censored394325
SecondarySymptomatic Skeletal Event Free Survival (SSE-FS) - Month

Symptomatic skeletal event-free survival (SSE-FS) was defined as the time from randomization to the first occurrence of an SSE or death from any cause, whichever occurred first. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

Time frame:
From randomization of the first participant to the first occurrence of an SSE event or death from any cause, whichever occurred first up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Median · Months
Symptomatic Skeletal Event Free Survival (SSE-FS) - Month
MonthsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Symptomatic Skeletal Event Free Survival (SSE-FS) - Month51.2 (47.2 to NA)39.7 (36.0 to 42.3)
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = <0.0001 (One-sided p-value.) · Hazard ratio (hr): 0.609 · 95% CI 0.516 to 0.718
SecondaryTime to First Symptomatic Skeletal Event (SSE) - Number of Events

Time to the first SSE was defined as the time from randomization to the first occurrence of an SSE. Identical to the definition used for SSE-FS. Death was not considered as an event in this endpoint. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the first occurrence of an SSE event up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Count of participants · Participants
Time to First Symptomatic Skeletal Event (SSE) - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number (%) of patients with event95108
Number (%) of patients censored556546
SecondaryTime to First Symptomatic Skeletal Event (SSE) - Month

Time to the first SSE was defined as the time from randomization to the first occurrence of an SSE. Identical to the definition used for SSE-FS. Death was not considered as an event in this endpoint. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

Time frame:
From randomization of the first participant to the first occurrence of an SSE event up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Median · Months
Time to First Symptomatic Skeletal Event (SSE) - Month
MonthsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Time to First Symptomatic Skeletal Event (SSE) - MonthNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = 0.0081 (One-sided p-value.) · Hazard ratio (hr): 0.712 · 95% CI 0.539 to 0.940
SecondaryTime to Initiation of Subsequent Antineoplastic Therapy - Number of Events

Time to initiation of subsequent systemic antineoplastic therapy was defined as the time from randomization to the initiation of first subsequent systemic antineoplastic therapy. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the initiation of first subsequent systemic antineoplastic therapy up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Count of participants · Participants
Time to Initiation of Subsequent Antineoplastic Therapy - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number (%) of patients with event219395
Number (%) of patients censored432259
SecondaryTime to Initiation of Subsequent Antineoplastic Therapy - Month

Time to initiation of subsequent systemic antineoplastic therapy was defined as the time from randomization to the initiation of first subsequent systemic antineoplastic therapy. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

Time frame:
From randomization of the first participant to the initiation of first subsequent systemic antineoplastic therapy up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Median · Months
Time to Initiation of Subsequent Antineoplastic Therapy - Month
MonthsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Time to Initiation of Subsequent Antineoplastic Therapy - MonthNA (NA to NA)25.3 (23.1 to 28.8)
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = <0.0001 (One-sided p-value.) · Hazard ratio, log: 0.388 · 95% CI 0.328 to 0.458
SecondaryTime to Worsening of Disease-Related Physical Symptoms - Number of Events

Time to worsening of disease-related physical symptoms was defined as the time from randomization to the first date a patient experienced an increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the first increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Count of participants · Participants
Time to Worsening of Disease-Related Physical Symptoms - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number (%) of patients with event351308
Number (%) of patients censored300346
SecondaryTime to Worsening of Disease-Related Physical Symptoms - Month

Time to worsening of disease-related physical symptoms was defined as the time from randomization to the first date a patient experienced an increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire. Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the first increase in disease-related physical symptoms based on the NCCN-FACT-FPSI-17 questionnaire up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Median · Months
Time to Worsening of Disease-Related Physical Symptoms - Month
MonthsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Time to Worsening of Disease-Related Physical Symptoms - Month19.3 (13.8 to 24.8)19.4 (15.4 to 27.6)
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = 0.7073 (One-sided p-value.) · Hazard ratio (hr): 1.043 · 95% CI 0.894 to 1.217
SecondaryTime to Initiation of Opioid Use for ≥7 Consecutive Days - Number of Events

Time to the initiation of opioid use for ≥7 consecutive days was defined as the time fromrandomization to the date of the first opioid use for ≥7 consecutive days. Data of opioid use related to cancer pain was included in the analysis, and opioid use for non-malignant causes was excluded. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data.

Time frame:
From randomization of the first participant to the first opioid use for ≥7 consecutive days up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Count of participants · Participants
Time to Initiation of Opioid Use for ≥7 Consecutive Days - Number of Events
ParticipantsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Number of patients with event92117
Number of patients censored559537
SecondaryTime to Initiation of Opioid Use for ≥7 Consecutive Days - Month

Time to the initiation of opioid use for ≥7 consecutive days was defined as the time fromrandomization to the date of the first opioid use for ≥7 consecutive days. Data of opioid use related to cancer pain was included in the analysis, and opioid use for non-malignant causes was excluded. Treatment period: until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. NA = Value cannot be estimated due to censored data

Time frame:
From randomization of the first participant to the first opioid use for ≥7 consecutive days up to 25 OCT 2021 cut-off date approximately 59 months
Reported as:
Median · Months
Time to Initiation of Opioid Use for ≥7 Consecutive Days - Month
MonthsDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Time to Initiation of Opioid Use for ≥7 Consecutive Days - MonthNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel · Log Rank · p = 0.0037 (One-sided p-value.) · Hazard ratio (hr): 0.688 · 95% CI 0.523 to 0.906
PrimaryOS From Date of Randomization Until Death From Any Cause - Month

Treatment period: treatment was provided for all patients, twice daily, until disease progression (symptomatic progressive disease, change of systemic antineoplastic therapy), unacceptable toxicity, consent withdrawal, withdrawal at the discretion of the investigator, death, or non-compliance. Active follow-up visits from the discontinuation of the darolutamide or placebo treatment period for up to 1 year or until the patient could no longer travel to the clinic, died, was lost to follow-up, or withdrew informed consent and actively objected to collection of further data. Long-term (Survival) follow-up period: After Active follow-up, patients continued to be contacted approximately every 12 weeks by phone. The end of the Survival follow-up period was defined as when the patient died, was lost to follow-up, withdrew consent, or at the end-of-study. Median, percentile and other 95% CIs were computed using Kaplan-Meier estimates. NA = Value cannot be estimated due to censored data

Time frame:
From randomization of the first participant until death from any cause up to 25 OCT 2021 cut-off date 533 OS events were reached (approximate 59 months)
Reported as:
Median · Month
OS From Date of Randomization Until Death From Any Cause - Month
MonthDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
OS From Date of Randomization Until Death From Any Cause - MonthNA (NA to NA)48.9 (44.4 to NA)

Adverse events

Collected over From start of study drug administration until 30 days after the last administration, including adverse event of all-cause mortality at any time during the study, up to cut-off date for the final completion analysis 11 APR 2023 (approximately 77 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Darolutamide (BAY1841788) + Docetaxel231/652 (35.4%)306/652 (46.9%)636/652 (97.5%)
Placebo + Docetaxel305/650 (46.9%)276/650 (42.5%)634/650 (97.5%)
Most frequent serious events
Showing 10 of 366
Most frequent serious events
EventDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders40/65239/650
PneumoniaInfections and infestations16/65221/650
Neutrophil count decreasedInvestigations18/65210/650
PyrexiaGeneral disorders9/65215/650
NeutropeniaBlood and lymphatic system disorders12/65214/650
Alanine aminotransferase increasedInvestigations6/6528/650
Urinary tract infectionInfections and infestations7/6527/650
Spinal cord compressionNervous system disorders2/6527/650
COVID-19 pneumoniaInfections and infestations7/6523/650
SepsisInfections and infestations6/6526/650
Most frequent other events
Showing 10 of 54
Most frequent other events
EventDarolutamide (BAY1841788) + DocetaxelPlacebo + Docetaxel
AlopeciaSkin and subcutaneous tissue disorders267/652264/650
FatigueGeneral disorders222/652215/650
ArthralgiaMusculoskeletal and connective tissue disorders186/652173/650
AnaemiaBlood and lymphatic system disorders185/652164/650
Oedema peripheralGeneral disorders175/652169/650
DiarrhoeaGastrointestinal disorders168/652157/650
Neutrophil count decreasedInvestigations165/652151/650
White blood cell count decreasedInvestigations155/652142/650
ConstipationGastrointestinal disorders149/652132/650
NauseaGastrointestinal disorders117/652134/650

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Darolutamide (BAY1841788) + DocetaxelPlacebo + DocetaxelTotal
<=18 years000
Between 18 and 65 years243234477
>=65 years408420828
Sex: Female, Male
Sex: Female, Male(Participants)Darolutamide (BAY1841788) + DocetaxelPlacebo + DocetaxelTotal
Female000
Male6516541305
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Darolutamide (BAY1841788) + DocetaxelPlacebo + DocetaxelTotal
Hispanic or Latino404989
Not Hispanic or Latino5615571118
Unknown or Not Reported504898
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Darolutamide (BAY1841788) + DocetaxelPlacebo + DocetaxelTotal
American Indian or Alaska Native000
Asian231245476
Native Hawaiian or Other Pacific Islander000
Black or African American262854
White345333678
More than one race628
Unknown or Not Reported434689
08

Study locations

322 sites
  • Chandler, Arizona 85224, United States
  • Tucson, Arizona 85724, United States
  • Beverly Hills, California 90211, United States
  • Duarte, California 91010, United States
  • Los Angeles, California 90073, United States
  • Palo Alto, California 94304, United States
  • Denver, Colorado 80211, United States
  • Washington D.C., District of Columbia 20007, United States
  • Boca Raton, Florida 33486, United States
  • Gainesville, Florida 32610, United States
  • Miami Beach, Florida 33140, United States
  • Tampa, Florida 33612, United States
  • Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60611, United States
  • Peoria, Illinois 61615, United States
  • Louisville, Kentucky 40202, United States
  • New Orleans, Louisiana 70112, United States
  • Baltimore, Maryland 21287, United States
  • Towson, Maryland 21204, United States
  • Boston, Massachusetts 02111, United States
  • Boston, Massachusetts 02114-2696, United States
  • Boston, Massachusetts 02215, United States
  • Detroit, Michigan 48202, United States
  • Billings, Montana 59102, United States
  • Omaha, Nebraska 68130, United States
  • Lebanon, New Hampshire 03756, United States
  • Camden, New Jersey 08103, United States
  • Englewood, New Jersey 07361, United States
  • Hackensack, New Jersey 07601, United States
  • Albuquerque, New Mexico 87109, United States
  • Buffalo, New York 14203, United States
  • New York, New York 10032, United States
  • Poughkeepsie, New York 12603, United States
  • Rochester, New York 14642, United States
  • The Bronx, New York 14061, United States
  • Concord, North Carolina 28025, United States
  • Winston-Salem, North Carolina 27157, United States
  • Cleveland, Ohio 44106, United States
  • Columbus, Ohio 43210, United States
  • Gahanna, Ohio 43230, United States
  • Kettering, Ohio 45409, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Bala-Cynwyd, Pennsylvania 19004, United States
  • Camp Hill, Pennsylvania 17011, United States
  • Pittsburgh, Pennsylvania 15212, United States
  • Charleston, South Carolina 29401, United States
  • Charleston, South Carolina 29414, United States
  • Greenville, South Carolina 29607, United States
  • Myrtle Beach, South Carolina 29579, United States
  • North Charleston, South Carolina 29406, United States
  • Dallas, Texas 75231, United States
  • Temple, Texas 76508, United States
  • Salt Lake City, Utah 84112, United States
  • Charlottesville, Virginia 22903, United States
  • Falls Church, Virginia 22042, United States
  • Richmond, Virginia 23284, United States
  • Everett, Washington 98201, United States
  • Milwaukee, Wisconsin 53226, United States
  • Sydney, New South Wales 2010, Australia
  • Sydney, New South Wales 2031, Australia
  • Adelaide, South Australia 5000, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Fitzroy, Victoria 3065, Australia
  • Wilrijk, Antwerpen 2610, Belgium
  • Antwerp, 2020, Belgium
  • Brussels, 1070, Belgium
  • Bruxelles - Brussel, 1200, Belgium
  • Ghent, 9000, Belgium
  • Gilly, 6060, Belgium
  • Namur, 5000, Belgium
  • Cachoeiro de Itapemirim, Espírito Santo 29308-020, Brazil
  • Salvador, Estado de Bahia 41253-190, Brazil
  • Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Belo Horizonte, Minas Gerais 30150-320, Brazil
  • Curitiba, Paraná 81520-060, Brazil
  • Natal, Rio Grande do Norte 59040-000, Brazil
  • Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Santo André, São Paulo 09060-650, Brazil
  • São Paulo, São Paulo 01246-000, Brazil
  • São Paulo, São Paulo 04014-002, Brazil
  • Rio de Janeiro, 20231-050, Brazil
  • Rio de Janeiro, 22793-080, Brazil
  • São Paulo, 01308-050, Brazil
  • Gabrovo, 5300, Bulgaria
  • Pleven, 5809, Bulgaria
  • Plovdiv, 4004, Bulgaria
  • Sofia, 1303, Bulgaria
  • Sofia, 1431, Bulgaria
  • Sofia, 1784, Bulgaria
  • Varna, 9010, Bulgaria
  • Vratsa, 3000, Bulgaria
  • Calgary, Alberta T2N 4N2, Canada
  • Edmonton, Alberta T6G 1Z2, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Montreal, Quebec H2L 4M1, Canada
  • Hefei City, Anhui Province, Anhui 230031, China
  • Beijing, Beijing Municipality 100034, China
  • Beijing, Beijing Municipality 100142, China
  • Beijing, Beijing Municipality 100730, China

Showing the first 100 of 322 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bogemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, Verholen F, Kuss I, Joensuu H, Smith MR. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16. PubMed 36795843 ↗
  • Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Manarite J, Muslin D, Farrington T, Tombal B. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. Future Oncol. 2022 Jul;18(21):2585-2597. doi: 10.2217/fon-2022-0433. Epub 2022 Jun 3. PubMed 35656777 ↗
  • Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino A, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Mendez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. PubMed 35179323 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Oct 2021, 58 months.

Results were first posted in Feb 2023, 1 year 3 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 58 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2016
First posted
Jun 15, 2016
StartActual
Nov 30, 2016
Primary completionActual
Oct 25, 2021
CompletionActual
Apr 11, 2023
Results first posted
Feb 24, 2023
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02799602
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 15, 2016
Start date
Nov 30, 2016
Primary completion
Oct 25, 2021
Completion
Apr 11, 2023
Results posted
Feb 24, 2023
Last update
Dec 4, 2025

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion